TK1和Ki-67在三阴性乳腺癌中的表达及其临床意义

doi:10.3760/cma.j.issn.1673-422X.2016.06.003

摘要/Abstract

摘要： 目的探讨胸苷激酶1（TK1）、增殖细胞核抗原Ki-67在三阴性乳腺癌（TNBC）中的表达及其临床意义。方法选取2009年6月至2010年12月在青岛大学医学院第二附属医院行保乳根治术或改良根治术的乳腺癌患者的肿瘤组织切片120例，其中TNBC 60例，非TNBC 60例。应用免疫组织化学法检测乳腺癌组织中TK1、Ki-67的表达，并分析二者在TNBC中的表达与患者临床病理特征的关系。结果 TK1在TNBC和非TNBC中的阳性表达率分别为83.33%、51.67%，差异有统计学意义（χ2=13.713，P=0.000）。Ki-67在TNBC和非TNBC中的阳性表达率分别为68.33%、31.67%，差异有统计学意义（χ2=16.133，P=0.000）。TNBC患者TK1的表达与组织学分级（χ2=6.125，P=0.013）相关，与发病年龄（χ2=0.809，P=0.369）、绝经状态（χ2=1.615，P=0.204）、肿瘤大小（χ2=0.054，P=0.816）、淋巴结转移（χ2=0.672，P=0.412）无关。TNBC患者Ki67的表达与组织学分级（χ2=13.145，P=0.000）、淋巴结转移（χ2=6.182，P=0.013）相关，与绝经状态（χ2=1.018，P=0.313）、发病年龄（χ2=2.377，P=0.123）、肿瘤大小（χ2=2.401，P=0.121）无关。TNBC患者TK1阳性表达与Ki-67阳性表达呈正相关（r=0.369，P=0.023）。生存分析显示，TK1阳性和阴性者的5年无瘤生存率分别为28.20%和66.70%，Ki-67阳性和阴性者的5年无瘤生存率分别为24.30%和64.30%，差异均有统计学意义（χ2=4.194，P=0.041；χ2=4.540，P=0.033）。结论 TK1、Ki-67在TNBC中均高表达，且其表达与组织学分级和患者生存期相关，可作为判断预后的参考指标。

关键词: 胸苷激酶, 增殖细胞核抗原, 乳腺肿瘤

Abstract: Objective To analyze the expressions of thymidine kinase 1 (TK1) and nuclearassociated antigen Ki-67 in triple negative breast cancer (TNBC) and their clinical significances. MethodsOne hundred and twenty tumor tissue sections of patients with breast cancer who were performed breast conservation treatment or modified mastectomy in the Second Affiliated Hospital of Qingdao University Medical College from June 2009 to December 2010 were collected, and there were 60 cases with TNBC and 60 cases with nonTNBC. The expressions of TK1 and Ki-67 in different breast tissues were detected by immunohistochemistry. The relationships between the expression status and clinicopathologic features were analyzed. ResultsThe positive expression rates of TK1 in TNBC and nonTNBC were 83.33% and 51.67% respectively, with a significant difference (χ2=13.713, P=0.000). The positive expression rates of Ki67 expression in TNBC and nonTNBC were 68.33% and 31.67% respectively, with a significant difference (χ2=16.133, P=0.000). In TNBC, the expression of TK1 was related to histological staging (χ2=6.125, P=0.013), but it was not related to onset age (χ2=0.809, P=0.369), menopausal stutas (χ2=1.615, P=0.204), tumor size (χ2=0.054, P=0.816) and lymphatic metastasis (χ2=0.672, P=0.412). In TNBC, the expression of Ki67 was related to histological staging (χ2=13.145, P=0.000) and lymphatic metastasis (χ2=6.182, P=0.013), but it was not related to menopausal stutas (χ2=1.018, P=0.313), onset age (χ2=2.377, P=0.123) and tumor size (χ2=2.401, P=0.121). The expression of TK1 was positively correlated with that of Ki67 (r=0.369, P=0.023). The results of survival analysis showed that the diseasefree survival rates of 5year were 28.20% and 66.70% in the TK1 positive group and TK1 negative group, and the diseasefree survival rates of 5year were 24.30% and 64.30% in the Ki-67 positive group and Ki-67 negative group, with significant differences (χ2=4.194, P=0.041; χ2=4.540, P=0.033). ConclusionTK1 and Ki-67 are highly expressed in TNBC, and their expressions are correlated with histological staging and survival, which are expected to become prognostic indicators.

Key words: Thymidine kinase, Proliferating cell nuclear antigen, Breast neoplasms

牛余超，姚远，马学真. TK1和Ki-67在三阴性乳腺癌中的表达及其临床意义[J]. 国际肿瘤学杂志, 2016, 43(6): 409-413.

Niu Yuchao*, Yao Yuan, Ma Xuezhen. Expressions and clinical significances of TK1 and Ki-67 in triple negative breast cancer[J]. Journal of International Oncology, 2016, 43(6): 409-413.

参考文献

［1］ Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basallike phenotype: a possible precursor to invasive basallike breast cancer［J］. Mod Pathol, 2006, 19(5): 617-621. DOI: 10.1038/modpathol.3800570. ［2］ Johnson LF, Rao LG, Muench AJ. Regulation of thymidine kinase enzyme level in serumstimulated mouse 3T6 fibroblasts［J］. Exp Cell Res, 1982, 138(1): 79-85. DOI: 10.1016/00144827(82)900933. ［3］刘广舒, 高云, 郭鹏, 等. C-erbB-2、Ki-67、nm23基因表达与乳腺癌腋窝淋巴结转移的相关性分析［J］. 实用预防医学, 2013, 20(3): 340-342. DOI: 10.3969j.issn.10063110.2013.03.032. ［4］王红梅, 魏尚典, 陈新文, 等. Ki67在乳腺癌中的表达及临床意义［J］. 中国普通外科杂志, 2012, 21(5): 616618. ［5］ He Q, Mao Y, Wu J, et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas［J］. Int J Oncol, 2004, 25(4): 945-953. DOI: 10.3892/ijo.25.4.945. ［6］ Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and longterm survival in patients with triplenegative breast cancer［J］. J Clin Oncol, 2008, 26(8): 1275-1281. DOI: 10.1200/JCO.2007.14.4147. ［7］ Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis［J］. Lab Invest, 2002, 82(11): 1525-1533. DOI: 10.1097/01.LAB.0000038508.86221.B3. ［8］ Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and Pcadherin: three molecular markers to distinguish basal phenotype in breast carcinomas［J］. Virchows Archiv, 2005, 447(4): 688-694. DOI: 10.1007/s00428-005-0010-7. ［9］杨雅洁, 温文, 关弘, 等. 乳腺癌中胸苷激酶1的表达及其临床意义［J］. 临床与实验病理学杂志, 2012, 28(5): 562-564. ［10］ He Q, Fornander T, Johansson H, et al. Thymidine kinase 1 in serum predicts increased risk of distant or locoregional recurrence following surgery in patients with early breast cancer［J］. Anticancer Res, 2006, 26(6C): 47534759. ［11］李斌, 曹剑霞, 成红霞, 等. 血清TK1含量在乳腺癌患者中的变化及临床意义［J］. 放射免疫学杂志, 2012, 25(5): 587-588. DOI: 10.3969/j.issn.10089810.2012.05.058. ［12］ Tan PH, Bay BH, Yip G, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death［J］. Med Pathol, 2005, 18(3): 374-381. ［13］李延辉. 乳腺增生性病变组织中ER、PR、c-erbB-2、p16和Ki-67的表达及意义［J］. 实用预防医学, 2009, 16(5): 1509-1511. ［14］阮永威, 田兴松, 侯连泽. 乳腺癌p16, p53基因蛋白和mRNA的表达及其意义［J］. 中国普通外科杂志, 2008, 17(5): 497-501. ［15］李振凤, 宋修岐, 邹晓, 等. 乳癌组织LRP16、Ki67及EGFR表达及其与预后关系［J］. 齐鲁医学杂志, 2013, 28(2): 124-126. DOI: 10.1172/qlyx201302010. ［16］付荣湛, 阮长乐, 于学智, 等. Ki67和DNA倍体与乳腺癌淋巴转移倾向［J］. 肿瘤学杂志, 2003, 9(6): 350-352. ［17］ Ceccarelli C, Trerè D, Santini D, et al. AgNORs in breast tumours［J］. Micron, 2000, 31(2): 143-149. ［18］任若冰, 许頳, 李亚芬, 等. 血清胸苷激酶1在乳腺肿瘤中的表达及其临床意义［J］. 中国癌症杂志, 2014, 24(1): 41-45. DOI: 10.3969/j.issn.1007-3969.2014.01.007.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.